182 related articles for article (PubMed ID: 23131393)
21. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT
Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433
[TBL] [Abstract][Full Text] [Related]
22. VE1 immunohistochemistry is an adjunct tool for detection of BRAF
Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S
J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C
Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190
[TBL] [Abstract][Full Text] [Related]
24. Validation of Immunohistochemistry for the Detection of
Gow CH; Hsieh MS; Lin YT; Liu YN; Shih JY
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234388
[No Abstract] [Full Text] [Related]
25. Diagnostic value of immunohistochemistry for the detection of the BRAF V600E mutation in colorectal carcinoma.
Ioannou M; Papamichali R; Samara M; Paraskeva E; Papacharalambous C; Baxevanidou K; Koukoulis G
J BUON; 2016; 21(3):618-25. PubMed ID: 27569082
[TBL] [Abstract][Full Text] [Related]
26. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
[TBL] [Abstract][Full Text] [Related]
27. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
28. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR
Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
30. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
31. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
Goeppert B; Frauenschuh L; Renner M; Roessler S; Stenzinger A; Klauschen F; Warth A; Vogel MN; Mehrabi A; Hafezi M; Boehmer K; von Deimling A; Schirmacher P; Weichert W; Capper D
Mod Pathol; 2014 Jul; 27(7):1028-34. PubMed ID: 24309328
[TBL] [Abstract][Full Text] [Related]
32.
Ahn HY; Lee CH; Lee MK; Eom JS; Jeong YJ; Kim YD; Cho JS; Lee J; Lee SJ; Shin DH; Kim A
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374289
[No Abstract] [Full Text] [Related]
33. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
[TBL] [Abstract][Full Text] [Related]
35. BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors.
Breton Q; Plouhinec H; Prunier-Mirebeau D; Boisselier B; Michalak S; Menei P; Rousseau A
Brain Behav; 2017 Mar; 7(3):e00641. PubMed ID: 28293477
[TBL] [Abstract][Full Text] [Related]
36. VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma.
Sajanti S; Sirniö P; Väyrynen JP; Tuomisto A; Klintrup K; Mäkelä J; Ristimäki A; Mäkinen MJ
Virchows Arch; 2014 Jun; 464(6):637-43. PubMed ID: 24722974
[TBL] [Abstract][Full Text] [Related]
37. [Immunohistochemistry using clone VE1 is an economic, specific and sensitive method for detecting the presence of BRAFV600E mutations in melanoma].
Etienne M; Oca F; Prunier-Mirebeau D; Croué A; Martin L
Ann Dermatol Venereol; 2018 Mar; 145(3):159-165. PubMed ID: 29221650
[TBL] [Abstract][Full Text] [Related]
38. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
Chen D; Qi W; Zhang P; Zhang Y; Liu Y; Guan H; Wang L
Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
